
MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors
Treatment with the novel CTLA-4–targeted engineered toxin body MT-8421 was safe and produced no grade 4 or 5 toxicities in patients with select advanced solid tumors, according to findings from the dose-escalation portion of a first-in-human phase 1 trial …